Interferon β (IFNβ) was suggested as a potential anti-fibrotic for NASH with its ability to downregulate fibrogenic genes associated with TGFβ-1 and MyD88 pathways [15]. This evidence concerns the gene MYD88 and metabolic dysfunction-associated steatohepatitis.